Could a popular Weight-Loss drug help—or Harm—Those with duchenne muscular dystrophy?
NCT ID NCT07642635
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether semaglutide (a GLP-1 drug used for weight loss) is safe for adolescents and young adults with Duchenne muscular dystrophy (DMD) who are also overweight or obese. The main concern is that the drug might reduce muscle mass, which is already weak in DMD. Participants will take either semaglutide or a placebo for 24 weeks, then all will receive semaglutide for another 40 weeks. The study monitors muscle mass, fat, heart and lung function, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
semaglutide (Rybelsus)
What this could lead to
If safe, this could offer a weight-loss option for people with Duchenne muscular dystrophy who struggle with obesity, potentially improving heart and metabolic health.
What could go wrong
This is an early-phase trial with only 30 participants. The main concern is that semaglutide might reduce muscle mass, which is already compromised in DMD. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY (DMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States